LGALS9 and B-cell chronic lymphocytic leukemia: By combining the assessment of the CLL disease course and the clinical merit of measuring plasma CXCL13 and galectin-9 concentrations in treatment-naive CLL patients, we found that measuring soluble CXCL13 and galectin-9 concentration could effectively determine both CLL disease activity and progression and predict treatment response.